SecBot SecBot
Insider Cluster (2 insiders) ·Filed Jun 18, 2026

PCVX

Vaxcyte, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed5mo ago
Insider cluster: 2 insiders, $542K total
Actionable Insight • Neutral

The CEO and CFO sales are immaterial in size and follow option exercises, consistent with routine tax/vesting-related selling. No bearish read-through. Monitor next quarterly results for any operational or pipeline updates that could drive sentiment.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$52.11
T+0 close · Jun 18, 2026 · via day close
Latest settled
+13.63%
T+60 · $59.21
Vs SPY
+11.88%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 22 $52.11entry
  2. T+1 · 5mo ago −0.29%α +1.16% · $51.96
  3. T+5 · 5mo ago +8.46%α +10.53% · $56.52
  4. T+20 · 4mo ago +7.85%α +8.00% · $56.20
  5. T+60 · 2mo ago +13.63%α +11.88% · $59.21
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two top C-suite executives at Vaxcyte (CEO and CFO) sold a combined ~$542K in open-market sales on June 18, 2026, following the exercise of stock options. The sales are small relative to the $7.3B market cap (~0.007%), making them routine and likely tax-related or liquidity-driven. No material bearish signal.

Key Financial Metrics

Direction
selling
Total Value
$542.0K
Insiders
2

Key Facts

  • CEO Grant Pickering sold 225 shares for ~$11.8K on June 18
  • CFO Andrew Guggenhime sold 10,000 shares for $530K on June 18
  • Both sales followed option exercises at nominal prices ($0 and $1.79/$5.35)
  • Total open-market sales: ~$542K, or 0.007% of $7.3B market cap
  • No other insiders made open-market purchases in the window

Financial Impact

~$542K in total open-market sales, trivial relative to $7.3B market cap

insider_holdings

Risk Factors

  • No material risk from this filing; the sales are too small to signal concern

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-PCVX-1781827713751

US Market Status

Market Closed · Opens Wed (13h 17m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 18, 2026